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 The effect of Daucus carota pentane-diethylether fraction 
on cancer cell motility and metastasis 
 
 
 
 Perla Z. Zgheib 
 
 
Abstract 
 
Daucus carota (DC) is a herb used in folklore medicine in Lebanon to treat 
numerous diseases and infections including cancer. Previous studies were done on 
the aqueous and methanolic plant extract in order to assess its anti-cancer, anti-
oxidant and anti-inflammatory activities. Recent studies in our labs have focused on 
assessing the anti-cancer and anti-oxidant effects of the oil extract and its fractions 
on various types of cancers in vivo and in vitro. This study aims to investigate the 
effect of DCO pentane-diethylether fraction on lung, skin, breast and glioblastoma 
cancer motility and metastasis. This was done through 2D, 3D and molecular assays. 
Upon treatment, a pronounced decrease in cancer cell motility was observed in the 
four cell lines used. The treatment also led to a decrease in cancer cell invasion and 
an increased cell adhesion.  In addition, a decrease in CDC42 activation levels, and 
an increase in Rac activation were detected. The significance of this study, which 
demonstrated a crucial effect of the pentane-diethylether fraction on cancer motility 
and metastasis, is towards reaching a potential cancer therapy specifically targeting 
cancer motility and metastasis. 
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Chapter 1 
LITERATURE REVIEW 
 
 
1.1. Cancer 
1.1.1. Introduction 
 Cancer accounts for 13% of total global deaths according to the world health 
association (WHO) (World Health Organization, 2010). Falling right after heart 
diseases, cancer would be considered a disease with high incidence. However, 
considering the fact that cancer could result from one cell escaping the normal cell 
cycle, and bearing in mind the number of cells in an organism, cancer is a low 
frequency disease. The cause of cancer is multifactorial and it can occur in the 
various organs and tissues in the organism. Different cancers are named mainly 
according to their location (American Cancer Society, 2013). For instance the major 
types are carcinomas; sarcomas and lymphomas are cancers occurring in the 
epithelial, mesenchymal and hematopoietic or lymphoid cells respectively. 
The development of cancer occurs when a single cell in the organism escapes 
the repair mechanism due to a distortion in its genetic materials and normal growth 
cycle. This cell starts developing the “Hallmarks of cancer” which include the 
induction of self proliferation, evasion of apoptosis and immunity, increased motility 
and invasion of tissues, and recruitment of normal cells and blood vessels to insure a 
proper “tumor microenvironment” (Szabó & Merks, 2013) .   
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1.1.2. Brain and other nervous system tumours 
1.1.2.1.Occurrence 
Brain and other nervous system tumours (CNS) account for 2.42% of all 
cancer mortalities (Siegel, Naishadham, & Jemal, 2013). 6.4 out of 100,000 people 
are diagnosed annually with these types of cancer with a noticeable elevated 
occurrence in males relative to females (Horner, et al., 2011) 
1.1.2.2.Symptoms and risk factors 
Symptoms characterizing Brain and other CNS tumors include difficulty in 
handling objects, blurred or double vision, headache, dizziness, vomiting, and 
difficulties in maintaining posture and walking (American Cancer Society, 2013) . 
Risk factors include genetic aspect such as family history, inherited 
polymorphisms in genes related to carcinogen metabolism, oxidative   metabolism, 
and DNA repair. Chemical carcinogens such as tobacco, asbestos, aflatoxin, 
exposure to ionizing or nonionizing radiation and biological carcinogens including 
viruses, bacteria, parasites and allergies(Wrensch, Minn, Chew, Bondy, & Berger, 
2002) 
1.1.3. Breast tumours 
1.1.3.1.Occurrence 
Breast cancer is one of the most prevalent cancers accounting for around 14.1% 
of all cancer incidence and 6.8% of all cancer deaths in 2012. In addition, it is most 
commonly diagnosed cancer and the second leading cause of cancer related death in 
women (Siegel, Naishadham, & Jemal, 2013). There are five different types of breast 
cancers divided in two main categories which are the noninvasive and invasive 
carcinoma. The most frequent types are the lobular and ductal types and (Jiang, 
Enomoto, & Takahashi, 2009) . 
1.1.3.2. Symptoms and risk factors 
Breast tumours fatality lies in the poor diagnosis since they are mostly 
undetectable at early stages where they can be easily treated.  New methods for early 
screening of breast cancer have been developed to increase the chances of survival. 
Breast self examination or BSE should be taught and practiced by every woman 
starting the age of twenty. Clinical breast examination should be done once every 
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three years for women in their twenties and thirties and a mammography once a year 
for women above the age of forty. Morphological changes in breast’s skin and 
nipples rarely manifest indicating the occurrence of the tumour (American Cancer 
Society, 2013). 
The risk for developing breast cancer increases with age until the reach of 
menopause where the risk starts decreasing.  Other elements that might contribute to 
increased occurrence of this cancer are increased fat and alcohol intake, weight, 
smoking, oral contraceptives, radiation, family history, age at menarche and 
menopause, age at first pregnancy and hormone replacement therapy (McPherson, 
Steel, & Dixon, 2000). 
1.1.4. Skin tumours 
1.1.4.1. Occurrence 
Although skin tumours are not considered high frequency cancers as they account for 
4.9% of all cancer types, their incidence have been increasing in the last 30 years 
among white individuals. The disease is 23 times more likely to hit white people than 
African American. In 2013, 12,650 cases of skin cancer related deaths are estimated 
to occur. If detected at an early stage basal, squamous cell tumours and melanomas 
are curable. Still, some skin cancers, mostly melanomas, metastasize to other sites 
decreasing the survival rate from 98% to 15%  (American Cancer Society, 2013). 
1.1.4.2. Symptoms and risk factors 
Skin cancers can look like any normal mole or skin infection, yet they can be 
differentiated from the latter for having an irregular size, shape and colour. An 
ABCD rule has been developped in order to detect this cancer in its early stages thus 
increasing the survival chances. A stands for Asymmetry, B is for the irregular 
border shape, C is for non-uniform colour and pigmentation and D is for a large 
diameter (more than 6mm). If a mole or skin lesion satisfies the above mentioned 
criteria it is most probably a tumour.  
  Risk factors include family history, genetic disorders involving the 
immune system, large number of benign moles, fair sensitive skin, and excessive 
exposure to sunlight and use of tanning booths (American Cancer Society, 2013). 
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1.1.5. Lung tumours 
1.1.5.1. Occurrence 
In 2013, lung cancer is estimated to be the second most prevalent cancer in both 
males and females and will account for more deaths than any other cancer type in 
both genders. Two types of lung cancer have been identified; the small cell type 
(15%) and the non-small cell type (84%) (American Cancer Society, 2013). The 5-
years survival rates of this cancer are very low (7%) which is probably due to the fact 
that the disease is usually spread by the time it is discovered (Parsons, Daley, Begh, 
& Aveyard, 2010). 
1.1.5.2. Symptoms and risk factors 
Computed Tomography Screening was proven to be the most effective technique for 
screening as it allows the detection of an increased number of small nodules relative 
to other techniques such as the X-ray scanning (Bach, et al., 2007). 
Smoking increases the risk of lung cancer by about 20-folds. Other factors include 
paint, diesel, and asbestos and arsenic fumes exposure in addition to radiation, 
organic chemicals and air pollution. 
1.1.6. Cancer classification 
 Cancer staging is very important for choosing the treatment and for better 
prognosis. Based on how big the tumour mass is at the primary site and whether it is 
contained or has metastasized to nearby or far tissues by the time it was diagnosed. 
Different systems have been developed to help in cancer classification. According to 
ACSC, cancer can be classified on the basis of its degree of tissue penetration and 
metastasis. For instance, “in situ” is the class for contained tumours, “local” for 
locally spread ones, “regional” for the regionally spread tumours and “distant” for 
invasive tumours which have reached remote organs and tissues. (American Cancer 
Society, 2013) 
  Although different cancer types may have different staging systems, the 
nowadays used system by clinicians is the TNM system. This system classifies the 
tumours according to the size at primary site, whether or not the lymph nodes are 
involved and the extent to which it has metastasized and invaded the distant tissues 
and organs. After classifying the tumours in T, N or M categories, they are further 
subdivided into five stages. For instance stage zero is for cancers in situ and stage 
four is for the most advanced and aggressive cancer (Astler & Coller, 1954). 
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1.2. Motility 
1.2.1. Normal cell motility cycle 
Chemotaxis is an important cellular process in the life of eukaryotes. For 
instance, cellular motility is crucial for the development of the organs and eventually 
the formation of the entire body.  Moreover, the newly formed muscle, endothelial 
and nerve cells travel to their proper locations in the limbs, blood vessel lining and 
nervous system respectively in the developing embryo. Most importantly, in the fully 
formed organisms, immune cells survey the body at all times to secure the body from 
possible pathogens and in the case of injuries these cells migrate to repair the wound 
(Lambrechts, Van Troy, & Am, 2004).   
Cells normally move in response to chemoattractants in the environment, and 
then motility is achieved through a shift between the polymerized and non 
polymerized actin filaments in the cytoskeleton.  Generally cells extend their 
protrusion towards the extracellular triggers they are exposed to. Protrusion 
structures like lamellipodia and filopodia attach though focal contacts at one end and 
detaches from the other end in order for the cell to move. While the focal contacts 
behind the protrusion border develop into focal adhesions, they drag the cell onwards 
as observed in figure 1(Lauffenburger & Horwitz, 1996). 
Cellular motility can reach a velocity of twenty meters per minute which is 
almost equivalent to a two hundred subunit per second polymerization rate. This is 
inconsistent with the in vitro findings which reported an approximate half subunit per 
second, alteration might be due to the effect of the actin binding proteins in the 
accelerated process (Zigmond, 1993). Another factor that is controlled by the actin 
binding proteins and is important for the locomotion of the cell is the localization and 
organization of the filaments (Small, Stradal, Vignal, & Rottner, 2002). 
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Figure 1: Figure 1: A schematic of the three stages of cell movement: after the 
direction of movement is established, the actin polymerization allows the expansion 
of a protrusion at the leading edge in this direction of movement. It then docks its 
leading edge to the ECM and detaches the other edge and at the cell body in order to 
move. Lastly, these dynamics lead to cellular movement which pulls the whole cell 
body forward by contraction forces generated. (Ananthakrishnan & Ehrlicher, 2007). 
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1.2.2. Altered cell motility 
Any imbalance or mutation in the gene coding for proteins involved in 
motility may result in several disorders including birth defects, immunity disorders, 
malignant and metastatic cancers, and many others. As mentioned above, motility is 
crucial for the development of the embryo as it allows the specialized and 
differentiated cells to reach their destined location. In fact, any mutation affecting the 
motility of these cells will lead to a defect in the developed organs. For example, a 
mutation in Shroom, vinculin, WAVE1-2, Abl and Arg coding genes cause a 
malformation of the nervous system and some of these mutations cause the death of 
the embryo. Moreover, a mutation in genes involved in motility within immune cells 
may lead to immunodeficiency which will disable the organism to fight any intrinsic 
or extrinsic pathogen (Lambrechts, Van Troy, & Am, 2004). 
In the case of cancer, mutations in the cells allow them to escape the normally 
highly regulated motility mechanism and become highly active.  Actin genes 
mutations, upstream regulatory genes alterations and variation in the levels of 
expression of actin associated proteins are possible grounds for the initiation of 
aberrant cellular activity. 
Mutations in genes such as β-actin have been observed in few cancer cases 
(Vandekerckhove, Leavitt, Kakunaga, & Weber, 1980; Leavitt, et al., 1987), 
mutations in the Rho-GTPases which regulate the actin binding proteins upstream or 
in Rho-GTPases regulatory proteins have also shown alterations in motility (Oxford 
& Theodorescu, 2003). In addition, either the down or upregulation of actin 
regulatory proteins may lead to increased motility depending on the protein and 
cancer types. For instance, restoring the expression levels of certain proteins leads to 
the regression of the metastatic phenotype observed (Lambrechts, Van Troy, & Am, 
2004).   
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1.2.3. Metastasis 
Metastasis is one of the most important cancer hallmarks. It describes the 
ability of a tumor to migrate to and colonize sites which are in close proximity to or 
remote from the primary site. This capability renders metastasis the key factor in the 
determination of cancer malignancy as the metastatic tumors tend to be irresponsive 
to conventional treatments. This evasion of treatments including surgery and 
chemotherapy is due to the versification of cells in the tumor at primary and 
metastatic sites (Fidler, 2003). 
Cell metastasis mechanism consists of alternated and interconnected steps. 
The first of which is the detachment of the single tumor cells from the primary tumor 
mass. This is achieved through the loss of the cell-cell bonds, and the invasion of the 
primary tumor tissues through the degradation of the extracellular matrix (ECM) 
located around the tumor and in the blood or lymph vessels walls. After reaching 
underlying blood or lymph vessels, it uses the flow of the tissue to move throughout 
the body. Due to the abrasive blood and lymph circulation, many of the invaded 
cancer cells die. The surviving cells have to extravasate and reach the target organ 
where it will reside and proliferate creating large tumor masses as shown in figure 2 
(Lambrechts, Van Troy, & Am, 2004). All these steps depend on the interaction 
between the neoplasms and the metastatic niches. In addition, macrophages were 
found to play an important role helping the tumor cells to metastasize. In fact, it was 
found to secrete metalloproteinases which assist the neoplastic cells in degrading the 
ECM and carving a path for them to move farther from the tumor. It was also shown 
that the macrophage released chemoattractants which help in recruiting the tumor 
cells to the blood vessels. This process which is supposed to be life saving in normal 
pathogenic processes could be fatal in cancer cases. Since the macrophage reaches 
the tumor through blood vessels, and as it starts secreting the chemoattractants all the 
way from the vessel to the tumor, it will eventually recruit the tumor cells towards 
the blood vessels  (Condeelis, Wycko, & Segall, 2000). 
 
 
 
 
9 
 
 
Figure 2: The main steps in the formation of a metastasis. 
 a: Cellular transformation and tumor growth. Growth of neoplastic cells must be 
progressive, with nutrients for the expanding tumor mass initially supplied by simple 
diffusion. b: Extensive vascularization must occur if a tumor mass is to exceed 1–2 
mm in diameter. c: Local invasion of the host stroma by some tumour cells occurs by 
several parallel mechanisms. Thin-walled venules, such as lymphatic channels, offer 
very little resistance to penetration by tumor cells. d: Detachment and embolization 
of single tumor cells or aggregates occurs next, most circulating tumor cells being 
rapidly destroyed. After the tumor cells have survived the circulation, they become 
trapped in the capillary beds of distant organs. e: Extravasation occurs next probably 
by mechanisms similar to those that operate during invasion. 
f: Proliferation within the organ parenchyma completes the metastatic process. To 
continue growing, the micrometastasis must develop a vascular network and evade 
destruction by host defenses (Fidler, 2003). 
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Many hypotheses rose to explain the mechanism of metastasis. Yet the 
adopted one is the “Seed and Soil” theory, proposed by Dr. Steven Paget. It suggests 
that cancer cells migrate to a specific site or niche due to the compatibility between 
the cell and the microenvironment in the metastatic site. Furthermore, observations 
indicate that both the cell (the Seed) and the environment of different organs (the 
Soil) are factors involved in the determination of the metastasis site.  A couple of 
studies demonstrated that out of 2.2×     injected tumor cells only 3.9×    reach 
the blood and only 3.3×    induce metastasis (figure 3). It was also shown that at 
prominent sites of metastasis, metastatic cells adhere to capillary beds and thus are 
tissue specific whereas in non-conventional metastatic sites, they adhere to venules 
(FidlerI.J., 1970). 
 
 
Figure 3: Metastatic efficiency 
Efficiency was determined by dividing the number in each column by the number in 
the previous column (Condeelis, Wycko, & Segall, 2000). 
 
1.2.4. Tumor invasion 
Tumor invasion is a very important step in the metastasis process. It can be 
divided into several major steps. After its detachment from the primary tumor site by 
proteolysis, the neoplasmic cell move to the near blood or lymph vessel’s membranes 
where it will adhere and degrade the extracellular matrix. It would be then carried by 
the intravascular fluid which will transport the cell to its destination. Reaching its 
destination, the cell would adhere again to the blood vessel, extravasate and migrate 
to its secondary site. As shown in figure 4, motility is a very important criterion in 
this process since without it the cell wouldn’t be able to migrate to nearby tissue to 
invade locally, nor would it be able to reach the blood/lymph vessel for establishment 
of remote metastatic sites  (Lambrechts, Van Troy, & Am, 2004).  
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Fig.4: The invasion process. Tumor invasion can be illustrated by seven successive 
steps. Step 1 is the movement of the actively dividing tumor cells from the primary 
tumor site towards the blood/lymph vessels after losing the cell–cell bonds. 
Rearrangements in the actin cytoskeleton as well as matrix degradation by 
proteolytic enzymes secreted by the tumor cells, will accompany this migratory step. 
The cells subsequently attach to and breach the basement membrane (step 2 and 3), 
gain access to the vessel and spread (step 4). A reverse process, again involving 
cytoskeletal rearrangements, occurs upon extravasation. Tumor cells adhere to the 
capillary endotheliae (step 5), penetrate them (step 6) and migrate through the 
extravascular tissue where they create a suitable microenvironment and newly attract 
blood supply, finally resulting in a secondary lesion or metastasis (step 7) 
(Lambrechts, Van Troy, & Am, 2004). 
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1.3. Rho family GTPases 
1.3.1. General Rho-GTPases characteristics 
Rho GTPases derives from the Ras superfamily and are a family of actin 
regulatory proteins. This group consists of small GTP-binding proteins and is further 
subdivided into various subfamilies (Takai, Sasaki, & Matozaki, 2001).  
The Rho-subfamily consists of 20 members including RhoA-H which were 
discovered as a Ras gene homolog, Rac1-3 and CDC42 (Madaule & Axel, 1985; 
Ridley & Hall, 1992; Ridley, Paterson, Johnston, Diekmann, & Hall, 1992; Shinjo, et 
al., 1990). It also includes actin polymerization regulating proteins e.g. WAVE, N-
WASP,  MRCKα/β, PAK1–6, ROKα/β which are a family of kinases, adaptors such as 
Par6 and many other specialized families. 
Rho GTPases are major factors in actin turnover management, cellular adhesions 
control and gene transcription regulators (Ridley, 2001). 
It is only when these proteins are bound to GTP that they satisfy their 
functions, in the GDP bound form they are inactive (Boettner & Van Aelst, 2002). In 
their active form, these guanosine binding molecules undergo a change in their 
effector-binding sites allowing their binding to downstream machinery and activating 
it. The activation is initiated due to upstream molecular stimuli which lead to the GDP 
dissociation and the binding of GTP (Etienne-Manneville & Hall, 2002). 
 More specifically the changes in the activation cycle are regulated by three 
major types of molecules. For instance, GAPs (GTPase activating proteins) and GEFs 
(guanine nucleotide exchange factors) act as agonists to allow the switch to the active 
form, and GDIs (GDP dissociation inhibitors) act to prevent the activation of the 
proteins (Ridley & Hall, 1992; Ridley, Paterson, Johnston, Diekmann, & Hall, 1992).    
RhoA (Ras homologous member A), Rac1 (Ras-related C3 botulinum toxin 
substrate 1), and CDC42 (cell division cycle 42) are the most prominently studied and 
investigated members of this family (Boettner & Van Aelst, 2002). Although 
regulation of actin was initially attributed to Rho A, lamellipodia formation for Rac 
and filopodia development for CDC42 (Bishop & Hall, 2000), recent observations 
have demonstrated that more complex functions and mechanisms are regulated by 
these molecules. For instance, in addition to its function in monitoring focal 
complexes/adhesion turnover, RhoA also has a function in regulating Rac-1 and 
CDC42 activity (El-Sibai, et al., 2008). Furthermore GTPases have the capability to 
activate each others, for instance CDC42 can initiate Rac activity which can 
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subsequently stimulate Rho. Thus these small molecules have crucial roles in 
polarising, directing, and moving the cell (Lambrechts, Van Troy, & Am, 2004). 
1.3.2. Rho A 
RhoA, found in the cytoplasm or plasma membrane, is a very important 
factor in cancer chemotaxis as it controls the contractility of actinomysin through the 
stimulation of stress fiber formation, and controls the turn over between mature and 
immature states of focal complexes/adhesions as observed in figure 5 (Adamson, 
Paterson, & Hall, 1992; Mitchison & Cramer, 1996; Ridley & Hall, 1992). These are 
established through its regulation mDia and profiling complex and the ROCK-LIMK 
pathway (ROCK myosin light chain) (Lambrechts, Van Troy, & Am, 2004). 
In fact Rho A is responsible for the stress filament development through the 
activation of actin-myosin contractile filaments. In addition, focal complexes which 
allow the lamellipodia to adhere to ECM and do not have any function in motility 
need Rho to induce their maturation into focal adhesions. This allows the cell to 
detach and move forward (Gupton & Waterman-Storer, 2006). The lamellipodia 
move over the focal adhesions present at the edges of the cells, leading them to 
detach (Rottner, Hall, & Small, 1999). The regulation of this mechanism is very 
crucial for motility. For instance, decreased cellular motility occurs due to the 
persistence of focal complexes which would keep the cells docked to the 
extracellular membrane (Cox, Sastry, & Huttenlocher, 2001). Many cancer types, 
especially metastatic cancers such as skin and colon cancers, were found to have 
altered RhoA expression (Karelsson, Pedersen, Wang, & Brakebusch, 2009). RhoA 
was also found to increase the invasion of colon cancer cells through an α6β4 
integrin-mediated pathway (Abecassis, Olofsson, Schmid, Zalcman, & Karniguian, 
2003). 
1.3.3. Rac1 
Rac is a Ras-related protein in the Rho family of GTPases. It plays important 
roles in cellular growth and motility, the organization of actin cytoskeleton and many 
others. Thus it is involved in the determination of cancer metastasis and malignancy 
(Hwang, et al., 2004) 
 After determining the direction of the movement, cells protrude their 
lamellipodia through the Rac-dependent regulation of gelsolin, cofilin and profiling 
through PI(4,5)-P2 (Lambrechts, Van Troy, & Am, 2004). In addition, Rac induces 
actin nucleation through the Arp2/3 actin nucleation pathway, stabilizes these 
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filaments through cofilin inhibition and prevents the capping of actin via PIP2 
production (Hall, 1998). 
Rac also stimulates the adhesion of the newly formed lamellipodia through 
recruitment and formation of focal complexes which allows the attachment of the 
latter to the ECM (Nobes & Hall, 1995; Rottner, Hall, & Small, 1999). Focal 
complexes consist of small molecules which usually attach to the edges of 
protrusions and anchoring the cells rather than helping them to move.   
 
1.3.4. CDC42 
Directional sensation and orientation of movement are first steps in 
chemotaxis. These are established through the function of CDC42 (cell division cycle 
42).  In addition to that, CDC42 was found to control the development of filopodia 
and to regulate many downstream located effectors through its CRIB binding domain 
which is a CDC42/Rac interactive domain (Burbelo, Drechsel, & Hall, 1995) 
 Like Rho A, CDC42 could be found in the cytoplasm of the cell or 
embedded in its plasma membrane (Ziman, et al., 1993).  
Found to be over expressed in breast and testicular cancers, CDC42 is 
suspected to be involved the evolution of the tumour (Karelsson, Pedersen, Wang, & 
Brakebusch, 2009). Interesting findings correlated this molecule to the lamellipodia 
development through a Rac-induced lamellipodia formation (Hall, 1998). 
 Moreover it was found to activate WAVE and consequently the Arp2/3-
complex which leads to enhanced actin-induced lamellipodia development.  
 
1.3.5. Role of Rho-GTPases in cancer malignancy 
Knowing the extent to which Rho-GTPases are involved in many aspects in 
the normal cell motility, it is most likely that they have an important role in 
determining the invasiveness of tumour cells (Wang, et al., 2003). In fact two of the 
most important factors in determining cancer malignancy are its abrasive 
proliferation and motility. The tumours also acquire a reduced cellular polarity and 
the ability to transform surrounding cells and ECM and exploit them to establish a 
perfect tumour microenvironment (Ridley, 2004). According to a recent study, 
comparing the expression of genes encoding proteins involved in actin regulation 
showed that there is an increase in their expression levels in metastatic breast 
tumours in comparison to non-metastatic breast cancer models (Wang, et al., 2003). 
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 In fact, in addition to the increased RhoA expression in skin and colon 
cancer and that of CDC42 in breast and testicular tumours, increased levels of RhoC 
mRNA where found in invasive melanomas and increased Rac3 transcription was 
observed in metastatic breast cancer (Ridley, 2004). 
Other conducted studies showed also an alternate expression of Rho GTPases 
regulators and effectors in many types of cancer (Karelsson, Pedersen, Wang, & 
Brakebusch, 2009). 
Therefore, understanding the function of this family and all the molecules 
controlling it and regulated by it, might present an opportunity to target malignant 
and metastatic tumours. In fact, as mentioned earlier, the abrasive cancer motility is 
its most important feature helping it to evade the currently applied treatments.  
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Figure 5: Maintenance of normal epithelial polarity. RHOA, RAC1, CDC42 and 
PAR6 are required for cell polarity. RHOA and RAC1 are important for the 
formation of cell junctions. b : Benign tumours: loss of polarity and multilayering. 
Inhibition of RAC1 leads to failure to deposit laminin asymmetrically and 
subsequent loss of polarity. Activation of RHOA also leads to loss of polarity, but 
antagonism of RHOA function by RHOE/RND3 overexpression leads to 
multilayering of epithelial cells. c: Locally invasive tumours: loss of tissue 
boundaries and increased motility. Modulation of RAC1 and RHO/ROCK activation 
can lead to loss of cell–cell junctions. Elevated activity of RHOA, ROCK, RAC1 and 
CDC42 can cause increased motility. RHOA and RAC1 regulate expression of 
proteases that facilitate motility by degrading the basement membrane and other 
extracellular matrix compounds. d: Metastasis to a distant site: intravasation and 
extravasation. RHO and ROCK are required for tumour cells to cross endothelial cell 
layers. RHOC promotes expression of angiogenic factors, leading to an increase in 
vascularization of the tumour (Sahai & Marshall, 2002). 
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1.4. Cancer treatments 
1.4.1. General 
Cancer treatments vary with the type and stage of the cancer. The most 
commonly used treatments include chemotherapy, radiation and surgery. In fact the 
determination of the stage of cancer is a crucial factor in the determination of the 
type of the treatment and its degree of aggressiveness. 
1.4.1.1.   Chemotherapy  
It is the use of drugs to treat cancer. Different drugs are used for different 
outcomes. Some are used to demolish the tumour cells, others to stop their 
distribution or proliferation. The administration of chemotherapeutic agents may be 
done alone, or as an adjuvant with treatments. Chemotherapeutic treatments are 
usually given in cycles of treatment and rest periods to allow the recovery of the 
normal cells in the body. It might be given systematically, topically and many other 
ways. 
Chemotherapy side effects arise from the fact that the drugs are not selective 
for the cancer cells. This causes the destruction of the normal cells in the body and 
especially the immune cells which are constantly dividing and moving to maintain a 
healthy, pathogen free organism. Side effects include low immunity, vomiting and 
nausea, changes in the skin, memory, sexual life, fertility problems and many others 
(American Cancer Society, 2007). 
1.4.1.2. Radiotherapy 
Another widely used therapy is the radiotherapy which consists of high-
radiation exposure of charged particles, X and gamma rays. These radioactive 
substances either release free radicals which damage the genetic material of the cell 
or directly affect the DNA of the cells leading to cell death or remission of division. 
Radiotherapy may be done either by external exposure to a beam of radiation or by 
brachytherapy which consists of the introduction of the radioactive substances to the 
tissue near the tumor. On the other hand radioactive iodine can be used in radiation 
therapy. It circulates through systemic circulation to eradicate the neoplastic cells. 
Just like chemotherapy, radiation therapy is not selective as it damages both 
normal and cancer cells leading to various side effects. Although radioprotective 
drugs could be used to prevent the damage on normal tissues, side effects such as 
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fatigue, hair loss, digestive damage, fibrosis, infertility, amnesia and even in some 
cases it can cause a second tumour may occur (American Cancer Society, 2010). 
1.4.1.3. Surgery 
Surgery is the best known type of treatment for contained tumours. It might 
be used for prevention, for instance in the case of inherited breast cancer genes, it is 
better that the breast are remove since more likely cancer will develop. Other types 
of surgery include diagnostic, staging, curative, debulking, palliative, restorative and 
constructive. The surgeon decides the type of surgery according to the size and 
degree of tumour containment. For instance, in the case of metastatic tumours, 
surgery might be inefficient. In addition to that, the type of organs hit or damaged by 
the tumour takeover and mass is important for deciding whether or not to perform 
surgery and its type (American Cancer Institute, 2011). 
1.4.1.4. Other types of treatments 
Other types of cancer therapies include targeted therapies which consist of 
targeting specific molecules by certain drugs. The original target of this type of 
therapy was estrogen, a female sexual hormone which attaches to its receptor (ER) 
endogenously activating its effectors including genes involved in proliferation. This 
normally present hormone is used by breast cancer cells to help them proliferate and 
create large tumour masses. FDA has approved many drug substances which target 
the estrogen receptor in breast cancer cells. Toremifene and tamoxifen are two 
examples of such drugs and members of the “selective estrogen receptor modulators” 
or SERM group. Another drug used is fulvestrant, it binds to these ERs activates 
their self-destruction mechanisms. Targeted therapies also include gene therapies and 
cancer vaccines therapies. 
Biological therapies or immune-modulators is the stimulation of the body’s 
own immune system to treat cancer; cryosurgery used to treat exogenous tumours 
consists of exposing these latter to liquid nitrogen or argon gas, hyperthermia which 
is the usage of high temperature to shrink the tumours and laser therapy are other 
kinds of cancer treatments (American Cancer Institute, 2011).  
Complementary and alternative medicine (CAM) 
 Due to the cost, pain and devastation from currently used cancer treatments, 
people with cancer tend to search for new and natural cures for cancer. Usually 
19 
 
patients adopt these types of treatments along with the conventional ones and thus 
their effects cannot be determined accurately. Alternative medicine usage has 
increased for the past two decades which indicates that it is somehow effective.  
According to the CAM national center in the USA, there are five different 
groups of CAM treatments. Ayurveda, an ancient Chinese medicine belongs to the 
first group of “alternative medical systems”. Prayers and meditations on the other 
hand, are part of the “mind-body interventions”. “Manipulation and body-based 
methods” are also a group described by the national center for CAM. Energy 
therapies using magnetic or other types of fields are a fourth group.  And the last 
most important group is the “biologically based therapies” which consists of dietary 
plans, phytotherapy or herbalism and many other natural substances (National Center 
for Complementary and Alternative Medicine, 2004). 
 
1.4.2. Phytotherapy 
 Phytotherapy or herbal medicine is the use of plant extracts for treatment and 
prevention of many diseases. After being extensively used in traditional medicine, it 
has become the main focus of scientists interested in drug development having 
reduced and mild toxicity as compared to many synthetic drugs (Tavares, et al., 
2008). Furthermore the submerge of new studies demonstrating the effective anti-
oxidative and anti-cancerous activity of plant extracts encouraged further 
investigations on many plants. The effect of phytotherapy and plant based diet in 
cancer prevention and reduction is now well established.  
In fact, it is established that plant’s secondary metabolites are an important 
source for new cancer drugs. Catharanthus roseus, Camptotheca acuminate, 
Erythroxylum pervillei, Centaurea schischkinii and Taxus brevifolia are examples of 
plants which have been found to have potent anti-cancerous activity (Joyce Nirmala, 
Samundeeswari, & Deepa Sankar, 2011). An example is a drug isolated from Taxus 
brevifolia  named Taxol. It is now used in the market to treat many types of cancers 
and was proven to be helpful against many cancer types including breast, lung, 
prostate, ovarian and many others. Its anti-cancerous activity derives from the fact 
that it inhibits proliferation through inhibition of mitosis  (Hait, Rubin, Alli, & 
Goodin, 2007). Since it was proven effective, many plants derived drugs are now 
being tested in clinical trial. 
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1.5. Daucus Carota 
1.5.1.  Description  
Daucus carota ssp. carota, a member of the family Umbelliferae (Apiacea), is a 
tall stiff biennial herb with spiny fruits.  Also called Bee’s Nest Plant, Bird’s Nest 
Weed, Bird’s Nest Root, Devil’s Plague, Garden Carrot and Queen Anne’s lace, it is 
mostly grown in dried-out fields or meadows. It is native to Europe and can be found 
in tropical Africa, southwest Asia, Australia, North America and South America. In 
addition to that it is thought to be the predecessor of cultivated carrot. In summer 
season, the umbels of Daucus carota(DC) blossom carrying hundreds of small white 
flowers. Stems of wild carrots are tall and branched and the leaves are alternate 
(Maxia, et al., 2009). 
1.5.2. Usage in traditional medicine 
Daucus carota is a plant that has been used in the Lebanese traditional 
medicine to protect against gastric ulcer, treatment for diabetes, and muscle back 
pain, to enhance liver function and boost immunity. It was also used in some 
Lebanese villages for cancer treatment (Wehbe, Mroueh, & C., 2009). The plant’s 
volatile oil was also used in the European folk medicine as an effective urinary 
antiseptic and anti-inflammatory drug for cystitis and prostatitis. It was and is still 
being used as an antifungal and a potent antibacterial agent now proven powerful 
against many pathogenic bacteria including Staphylococcus aureus, Escherichia coli 
and Bacillus cereus (Maxia, et al., 2009).Nowadays it is used as a vasodilator, 
antilithic, carminative,diuretic, cholesterol regulator, antispasmodic, 
hepatoprotective, antisteroidogenic and for treating jaundice and stomach disorders . 
Oils extracted from DC herbs of different geographical origin are not completely 
identical in their composition. Nonetheless, it was found that monoterpenes and 
sesquiterpenes are present in all the oils extracted from leafs, umbels and stems 
independent of the geographical origin of the herb (Maxia, et al., 2009).  
For instance, Widdrol, one of the compounds present in Daucus carota oil 
extract (DCOE), has been also shown to inhibit the proliferation of human colon 
adenocarcinoma cells. In addition, β-selinene also found in DCOE exhibited anti-
tumor activities against lung, breast, and prostate cancer cell lines (Mazzio & 
Soliman, 2009). Another example is sesquiterpenes along with other components 
found in the plant extract were found to have a potent anti-cancerous activity against 
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many cancer types both in vivo and in vitro (Da Silva, Figueiredo, & Yano, 2007). 
1.5.3. Work in the lab 
Studies in our labs have shown previously the effective anticancer activity of 
the aqueous DC extract against human promyelocytic leukemia HL-60 cells. The DC 
aqueous extract’s effectiveness on the stimulation of differentiation and on 
proliferation inhibition was proven (Mroueh, El Ghaziri, & Daher, 2011). 
Furthermore, a study on the effect of the aqueous and methanolic extracts of the wild 
carrot umbels against inflammation (acute and chronic) and gastric ulcer showed 
significant anti-inflammatory and anti-ulcer activities (Wehbe, Mroueh, & C., 2009). 
Other studies on the effect of the oily extract against chemically (DMBA-TPA) 
induced skin carcinogenesis in mice showed significant chemopreventive activity 
(AbouZeinab, Mroueh, & Daher, 2008). 
Currently in vitro and in vivo experiments are being performed to assess the 
effect of the crude oil as well as fractionated oil on mice and various cell lines. It was 
found that the crude oil exhibits in vivo anti-oxidant activity and in vitro anti-cancer 
(on four cell lines CaCo-2, HT-29, MCF-7 and MDA). The crude oil was then 
fractionated over silica gel column chromatography and a solvent system was applied 
yielding four different fractions. Pentane was used to extract F1, diethyl and pentane 
for F2 extraction, chloroform for F3 extraction and a mixture of chloroform and 
methanol for F4 extraction. The effect of each fraction was assessed using cell culture 
techniques.  The      of each fraction was assessed on the four cell lines, CaCo-2, 
HT-29, MCF-7 and MDA. F1 and F2 fractions were found to possess the highest 
observable activity recording an      around 25µg/ml. On the other hand, the F3 and 
F4 fractions were found to have moderate activity with an      higher than 25µg/ml  
(Shebaby, et al., 2012). 
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1.6. Purpose of the study 
After assessing the effect of DCO pentane-dithylether fraction on two 
important factors in cancer malignancy, which are proliferation and apoptosis, it is 
still important to investigate its effect on cancer motility and metastasis. Thus the aim 
of the study is to look at the effect of this fraction of DC on cancer motility and 
metastasis using various imaging and motility techniques. 
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Chapter 2 
Materials and Methods 
2.1.     Sample collection and oil extraction 
Mature umbels of Daucus carota (Linnaeus) ssp. carota were collected at the 
post flowering period between August and September from their natural habitat in 
Lebanon. The plant was identified according to the characteristics described in 
‘Handbook of Medicinal Herbs’ (Van Wyk and Wink, 2004) and confirmed by Dr. 
A. Houri, a Lebanese plant expert at the Lebanese American University. Stripped 
umbels were air dried in the shade and then cut into small pieces for oil extraction. 
Leaves were soaked in methanol/acetone (1:1) for 72 hours. The extract was then 
filtered and evaporated to dryness under reduced pressure. The residue was 
centrifuged, and the oil was dried over anhydrous sodium sulfate. The final yield 
(3.47%) was stored in a closed amber bottle at 4˚C until use. 
 
2.2.    Oil fractionation 
The DCOE (30 g) was chromatographed on a silica gel column (230–400 
mesh; 47 cm by 2.5 cm). The first fraction (F1, 7.92 g, colourless) was eluted with 
pentane (100%, 1L), the second fraction (F2, 8.12 g, yellow) with pentane:diethyl 
ether (50:50; 1L), the third fraction (F3, 6.41 g, dark green) with diethyl ether (100%; 
1L) and the third fraction (F4, 5.42 g, dark green) with chloroform: methanol (50:50; 
1L). The F2 fraction was used in this study since it was proven to be the most 
effective. And a concentration of 25ug/ml was used since it is the concentration 
shown to be the approximate IC50 in all cell lines chosen. 
2.3.   Cell line and cell culture 
The human breast cancer cell line (MDA-MB231), human astrocytoma cell 
line (SF-268), human lung adenocarcinoma (A549) and human skin melanoma 
(B16F-10) were maintained in DMEM containing 10% fetal bovine serum (FBS) and 
100U penicillin/streptomycin at 37°C, 5% CO2 in a humidified chamber. 
 
 
24 
 
2.4.   Wound healing assay 
Cells were grown to confluence on culture plates and a wound was made in the 
monolayer with a sterile pipette tip. After wounding, the cells were washed to remove 
debris and new medium was added. Phase-contrast images of the wounded area were 
taken at 0 and consecutive hour after wounding. Wound widths were measured at 11 
different points for each wound, and the average rate of wound closure was calculated 
in m/hr. 
2.5.    Motility assay  
For motility analysis, images of cells moving randomly in serum were 
collected every 60 seconds for 2 hours using a 20X objective. During imaging, the 
temperature was controlled using a Nikon heating stage which was set at 37°C. The 
medium was buffered using HEPES and overlayed with mineral oil. The speed of cell 
movement was quantified using the ROI tracker plugin in the ImageJ software, which 
was used to calculate the total distance travelled by individual cells. The speed is then 
calculated by dividing this distance by the time (120 minutes) and reported in m/min. 
The speed of at least 5 cells for each condition was calculated. The net distance 
travelled by the cell was calculated by measuring the distance travelled between the 
first and the last frames.  
2.6.    Invasion assay 
Cells were transfected with either control or StarD13 siRNAs and invasion 
assay was performed 48hrs following treatment period using the collagen-based 
invasion assay (Millipore) according to manufacturer’s instructions. Briefly, 24hrs 
prior to assay, cells were starved with serum free medium. Cells were harvested, 
centrifuged and then resuspended in quenching medium (without serum). Cells were 
then brought to a concentration of 1x10
6 
cells/ml. In the meantime, inserts were pre-
warmed with 300l of serum free medium for 30min at room temperature. After 
rehydration, 250l of media was removed from inserts and 250l of cell suspension 
was added. Inserts were then placed in a 24-well plate, and 500l of complete media 
(with 10% serum) was added to the lower wells. Plates were incubated for 24hrs at 
37
o
C in a CO2 incubator. Following incubation period, inserts were stained for 20min 
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at room temperature with 400l of cell stain provided with the kit. Stain was then 
extracted with extraction buffer (also provided). 100ul of extracted stain was then 
transferred to a 96-well plate suitable for colorimetric measurement using a plate 
reader. Optical Density was then measured at 560m.  
 
2.7.    Pull down assays  
Cells were lysed and incubated with GST-CRIB or GST-RBD and the pull-
down assay performed using the RhoA/Rac1/Cdc42 Activation Assay Combo Kit 
(Cell BioLabs) following the manufacturer’s instructions. GTP-RhoA, GTP-Rac1 or 
GTP-Cdc42 was detected by western blotting using the anti-RhoA, anti-Rac1 or anti-
Cdc42 antibodies provided in the kit.  
2.8.    Adhesion assay 
96-well plates were coated with collagen using Collagen Solution, Type I from 
rat tail (Sigma) overnight at 37°C then washed with washing buffer (0.1% BSA in 
DMEM). The plates were then blocked with 0.5% BSA in DMEM at 37°C in a CO2 
incubator for 1 hour. This was followed by washing the plates and chilling them on ice. 
Meanwhile, the cells were trypsinized and counted to 4x10
5
 cell/ml.  The cells were 
added in each well and incubated at 37°C in a CO2 incubator for 30 minutes. The 
plates were then shaken and washed 3 times. Cells were then fixed with 4% 
paraformaldehyde at room temperature for 10 minutes, washed, and stained with 
crystal violet (5mg/ml in 2% ethanol) for 10 minutes. Following the staining with 
crystal violet, the plates were washed extensively with water, and left to dry 
completely. Crystal violet was solubilised by incubating the cells with 2% SDS for 30 
minutes. The absorption of the plates was read at 550 m using an ELISA plate reader.  
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2.9.   Immunostaining 
The cells were plated on cover slips, and the appropriate treatment was 
applied. Cells were fixed with 4% paraformaldehyde for 10 minutes, and 
permeabilized with 0.5% Triton-X100 for 10 minutes. To decrease background 
fluorescence, cells were rinsed with 0.1M glycine then incubated with 0.1M glycine 
for 10 minutes. For blocking, cells were incubated 4 times with 1% BSA, 1% FBS in 
PBS for 5 minutes. Samples were stained with rhodamine phalloidin for 30 minutes. 
Fluorescent images of cells stained with were taken using a 60X objective on an 
upright fluorescent microscope. 
2.10.  Statistical analysis 
All the results reported represent average values from three independent 
experiments. All error estimates are given as ± SEM. The p-values were calculated 
by t-tests or chi-square tests depending on the experiment.    
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Chapter 3 
Results 
3.1. Treatment with F2 fraction decreases cell motility 
3.1.1. Effect of treatment on A549 lung cell line  
3.1.1.1. Effect on wound healing ability 
The first thing to look at in order to assess the effect of the fraction on A549 
motility is the effect on its wound healing ability. The cells were plated, treated after 
24 hrs and then a wound was performed and cells were fed with serum free media. 
Pictures were taken at 0 hrs and 22 hrs later. The results assessed using the image J 
software showed a decrease in wound closure in around 82%. The cells treated only 
with DMSO had an average rate of 4.71µm/hr whereas cells treated with 25µg/ml of 
the F2 fraction have closure rate of 0.84 µm/hr(Figure 6).  
 
Figure 6: DC F2 fraction inhibits the wound closure ability of A549 cell line.  A) 
A549 cells were grown in a monolayer then treated after 24 hrs. 24 hrs after 
treatment, cells were wounded imaged at 0hrs and left to recover the wound for 22hrs 
where the wounds were imaged again at the same frame. B) Quantification for A. 
Wound widths were measured at 12 different points for each wound and the average 
rate of wound closure for the DMSO and F2 treated cells was calculated in µm/hr. 
The decrease was significant with a p- value less than 0.05.  
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  3.1.1.2. Effect of treatment on A549 lung cell line 2D motility 
After plating the cells and treating them with DMSO or 25µg/ml, images 
were taken every 60 seconds for 120 frames. The average cell speed, measured using 
the image J software and showed a decrease in cellular motility in about 71%. The 
average obtained for DMSO is 1.453561 µm/min and that of 25µg/ml treated cells is 
0.426733µm/min (Figure7). 
 
 
 
Figure 7: Treatment with F2 fraction inhibits motility of A549 cells. 
Quantification of the cell speed in µm/min using image J. The decrease was 
significant with a p-value less than 0.005. 
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3.1.2. Effect of treatment on B16F-10 melanoma cell line  
3.1.2.1. Effect on wound healing ability 
The first thing to look at in order to assess the effect of the fraction on B16F-
10 motility is the effect on its wound healing ability. The cells were plated, treated 
after 24 hrs and then a wound was performed and cells were fed with serum free 
media. Pictures were taken at 0 hrs and 6 hrs later. The results assessed using the 
image J software showed a decrease in wound closure in around 63%. The cells 
treated only with DMSO had an average rate of 8.28µm/hr whereas cells treated with 
25µg/ml of the F2 fraction the closure rate is 3.04 µm/hr (Figure 8).  
 
Figure 8: DC F2 fraction inhibits the wound closure ability of B16F-10 cell line.  
A) B16F-10 cells were grown in a monolayer then treated after 24 hrs. 24 hrs after 
treatment, cells were wounded imaged at 0hrs and left to recover the wound for 6 hrs 
where the wounds were imaged again at the same frame. B) Quantification for A. 
Wound widths were measured at 12 different points for each wound and the average 
rate of wound closure for the DMSO and F2 treated cells was calculated in µm/hr. 
the results were significant and with a p- value less than 0.05.  
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3.1.2.2. Effect of treatment on B16F-10 melanoma cell line 2D motility 
After plating the cells and treating them with DMSO or 25µg/ml, images were taken 
every 60 seconds for 120 frames. The average cell speed, measured using the image J 
software showed a decrease in cellular motility in about 80.5%. The average obtained 
for DMSO is 1.9263µm/min and that of 25µg/ml F2 treated cells is 0.3748µm/min 
(figure 9). 
 
 
              
Figure 9: Treatment with F2 fraction inhibits motility of B16F-10 cells.  
Quantification of the cell speed in µm/min using image J. the results were significant 
with a p-value less than 0.005. 
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3.1.2. Effect of treatment on MDA-MB231 breast cell line  
3.1.2.1. Effect on wound healing ability 
The first thing to look at in order to assess the effect of the fraction on MDA-
MB231 motility is the effect on its wound healing ability. The cells were plated, 
treated after 24 hrs and then a wound was performed and cells were fed with serum 
free media. Pictures were taken at 0 hrs and 24 hrs later. The results assessed using 
the image J software showed a decrease in average wound rate closure in around 
75%. The cells treated only with DMSO had a rate of 19.95µm/hr whereas cells 
treated with 25µg/ml of the F2 fraction had a rate of 4.89 µm/hr(Figure 10).  
 
Figure 10: DC F2 fraction inhibits the wound closure ability of MDA-MB231 
cell line.  A) MDA-MB231 cells were grown in a monolayer then treated after 24 
hrs. 24 hrs after treatment, cells were wounded imaged at 0hrs and left to recover the 
wound for 24hrs where the wounds were imaged again at the same frame. B) 
Quantification for A. Wound widths were measured at 12 different points for each 
wound and the average rate of wound closure for the DMSO and F2 treated cells was 
calculated in µm/hr. The decrease was significant and with a p-value less than 0.05.  
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3.1.2.2.  Effect of treatment on MDA-MB231 breast cell line 2D motility 
After plating the cells and treating them with DMSO or 25µg/ml, images 
were taken every 60 seconds for 120 frames. The average cell speed, measured using 
the image J software showed a decrease in cellular motility in about 65.5%. The 
average obtained for DMSO is 1.52305µm/min and that of 25µg/ml F2 treated cells 
is 0.52445µm/min (figure 11). 
 
 
              
Figure 11: Treatment with F2 fraction inhibits motility of MDA-MB231 cells. 
Quantification of the cell speed in µm/min using image J. The decrease was 
significant with a p-value less than 0.005. 
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3.1.3. Effect of treatment on SF-268 glioblastoma cell line  
 
3.1.3.1. Effect on wound healing ability 
The first thing to look at in order to assess the effect of the fraction on SF-268 
motility is the effect on its wound healing ability. The cells were plated, treated after 
24 hrs and then a wound was performed and cells were fed with serum free media. 
Pictures were taken at 0 hrs and 6 hrs later. The results assessed using the image J 
software showed a decrease in average raye of wound closure in around 63%. The 
cells treated only with DMSO had a rate of 30.057µm/hr whereas cells treated with 
25µg/ml of the F2 fraction the closure rate is 10.98µm/hr (Figure 12).  
 
Figure 12: DC F2 fraction inhibits the wound closure ability of SF-268 cell line.  
A) SF-268 cells were grown in a monolayer then treated after 24 hrs. 24 hrs after 
treatment, cells were wounded imaged at 0hrs and left to recover the wound for 6 hrs 
where the wounds were imaged again at the same frame. B) Quantification for A. 
Wound widths were measured at 12 different points for each wound and the average 
rate of wound closure for the DMSO and F2 treated cells was calculated in µm/hr. 
The decrease was significant and with a p-value less than 0.05.  
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3.1.3.2. Effect of treatment on SF-268 glioblastoma cell line 2D motility 
After plating the cells and treating them with DMSO or 25µg/ml, images were taken 
every 60 seconds for 120 frames. The average cell speed, measured using the image J 
software showed a decrease in cellular motility in about 37.6%. The average obtained 
for DMSO is 0.867µm/min and that of 25µg/ml F2 treated cells is 0.541µm/min( 
Figure 13). 
 
 
              
 
Figure 13: Treatment with F2 fraction inhibits motility of SF-268 cells.  
Quantification of the cell speed in µm/min using image J. The decrease was 
significant with a p-value less than 0.005. 
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3.2. Treatment with F2 fraction decreases the 3D invasion of cells 
After observing a potent effect on the inhibition of 2D motility, it was 
interesting to investigate the effect on 3D motility through the invasion assay. FBS is 
used as a chemoattractant in this technique. Cells are placed in a chamber coated 
with collagen with serum free media and allowed to migrate to the other chamber 
containing FBS. As expected, there was nearly a half-fold decrease in cell invasion 
as compared to the DMSO treated cells (Figure 14). 
 
Figure 14: treatment with 25µg/ml of F2 fraction inhibits invasion of cancer 
cells. A) Representative micrographs of invaded cells on the bottom side of the 
membrane stained with cell stain according to assay instruction. Cells with DMSO 
and F2 treated cells were allowed to invade towards 10% FBS for 24 hrs. B) Cell 
stain was extracted and colorimetric measurements were taken at 560 µm. Data is 
measured in arbitrary units. The decrease was significant with p-value less than 0.05. 
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3.3. The effect of treatment with F2 fraction on molecular      regulators 
of cellular motility 
Pull down assays were done to observe the effect on the molecular regulators 
of cellular motility. 
3.3.1 Effect of treatment on Rho activation 
Looking at Rho activation using pull down assay a decrease in Rho 
expression was noticed. This is expected since it is consistent with the fact that the 
treatment with the DC fraction decreased cellular motility (Figure 15). 
 
Figure 15: Rho activation in treated versus control. Cells were treated with 
DMSO or F2 fraction. The cells were then lyzed and incubated with GST-RBD 
(Rhotekin binding domain) to pull down active Rho. The samples were then blotted 
with Rho antibodies. A) The bands from active RhoA gels were quantitated using 
ImageJ and normalised to the amount of total proteins. B) Gel bands with total Rho 
in the right panels and active Rho on the left. 
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3.3.2 Effect of treatment on Rac activation 
Looking at Rac activation using pull down assay an increase in Rac 
expression was noticed. This is expected since it might be leading to an increased 
adhesion which might have decreased cellular motility (Figure 16). 
 
 
Figure 16: Rac activation in treated versus control. Cells were treated with 
DMSO or F2 fraction. The cells were then lyzed and incubated with GST-CRIB 
(Cdc42 and Rac interactive binding domain) to pull down active Rac. The samples 
were then blotted with Rac antibodies. A) The bands from active Rac gels were 
quantitated using ImageJ and normalised to the amount of total proteins. B) Gel 
bands with total Rac in the right panels and active Rac on the left. 
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3.3.3 Effect of treatment on CDC42 activation 
Looking at CDC42 activation using pull down assay a decrease in CDC42 
expression was noticed. This is expected since it is consistent with the fact that the 
treatment with the DC fraction decreased invasion (Figure 17). 
 
Figure 17: CDC42 activation in treated versus control. Cells were treated with 
DMSO or F2 fraction. The cells were then lyzed and incubated with GST- CRIB 
(Cdc42 and Rac interactive binding domain) to pull down active CDC42. The 
samples were then blotted with CDC42 antibodies. A) The bands from active CDC42 
gels were quantitated using ImageJ and normalised to the amount of total proteins. B) 
Gel bands with total CDC42 in the right panels and active CDC42 on the left. 
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3.4. Treatment with DC fraction increases cellular adhesion to collagen 
Since it was shown to increase Rac activation, and thus increase stabilization 
it was intriguing to look at the effect on adhesion. The results were consistent with 
the Rac pull down experiment and showed an increase in more than half a fold in 
cellular adhesion to collagen (Figure 18). 
 
Figure 18: The Effect of Daucus Carota F2 Fraction on Cell Adhesion. Crystal 
was solubilised and the absorption of the plates was read at 560 nm using an ELISA 
plate reader. Data is measured in arbitrary units and normalised to the control. The 
results were significant where p-value is less than 0.005. 
 
 
 
 
 
 
 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
F
o
ld
 I
n
cr
ea
se
 i
n
 C
el
l 
A
d
h
es
io
n
 
DMSO 
The Effect of Daucus Carota F1 Fraction 
on Cell Adhesion 
25 µg/ml 
* 
40 
 
3.5. Treatment with DC fraction decreased the formation of stress fibers 
Since it was shown to decrease Rho activation, and thus decrease actin turn 
over and formation of actin stress fibers, it was intriguing to look at the effect using 
immunostaining techniques. After the cells were plated and treated, they were fixed 
and stained using Rhodamine phalloidin conjugated to a secondary antibody. The 
results were consistent and showed a decrease in stress fibers (Figure 19). 
 
Figure 19: effect of treatment on Rhodamine phalloidin staining. A decrease in 
actin filaments was observed on the right panel (25µg/ml) relative to the left 
(DMSO). 
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Chapter 4 
Discussion 
As mentioned, plants and herbs have been the source of many drugs used in 
current chemotherapeutic treatments. In fact, phytochemicals were found to have a 
wide range of effects on various cancer types including inhibition of proliferation and 
induction of apoptosis. These effects were observable in vitro on various cancer cell 
lines and in vivo (Nirmala, Samundeeswari, & Sankar, 2011). 
In order to assess the possible anti- tumorigenic potential of various 
phytochemicals, their effects on cancer cell cycle, programmed cell death, 
inflammation and oxidative stress, resistance to other drugs and finally on cancer cell 
invasiveness and malignancy must be evaluated. Various phytochemicals showed 
promising anti-cancerous potentials using these guidelines (Limin, Ka-Lung, Tin Oo, 
Chi, & Ah-Ng, 2010). For example, reservatrol, a compound made by certain plants 
in response to pathogenic infections, was found to have all of the previously 
mentioned effects. Most recently, it was found to inhibit the metastasis and invasion 
of metastatic lung cancer (Heyong, et al., 2013).  
Previous studies have shown that DC crude oil extract and its different 
fractions have been shown to be effective as anti-inflammatory, antioxidants and 
anti-cancerous agents (Shebaby, et al., 2012). However, there are no studies 
conducted to assess its effect on cancer cell motility and metastasis.  
Among the four fractions obtained, the F2 and F2 fractions were proven to be 
the most effective fractions using various assays and having an IC50 less than 
25ug/ml (unpublished data). In this study, since the first sets of data showed that F2 
is more effective than F0 in motility inhibition, the study was carried on using the F2 
fraction. 
There are two types of cellular motility in vivo, the two-dimensional, and the 
three-dimensional motility. In-vitro experiments testing the effect of DC F2 fraction 
on motility should investigate its effect on both of these two types. The experiments 
were done on four cancer cell lines. Breast cancer cell line MB-MDA-231 was 
chosen since it is a metastatic cancer cell line and was shown to have noticeable 
motility in vitro compared to its MCF-7 counterpart which appeared to be less 
motile. Melanoma cell line B16F-10 was also used since it was shown to be 
metastatic and motile. A549 and SF-268 cell lines were also used for their motility 
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profiles and availability. The adhesion, invasion, pull-down and immunostaining 
assays shown were done only on the B16F-10 cell line since the effect of the 
treatment was mostly pronounced in this cell line and because of time limitations. 
The effect on the two-dimensional motility was measured using the wound 
healing and time lapse experiments. Both experiments showed a pronounced effect of 
the fraction on the four cell lines. In fact, upon treatment with the F2 DC fraction, the 
rate of wound closure decreased indicating a decrease in motility since the cells were 
treated with serum free media. The image J software also indicated a decrease in 
cellular motility upon the treatment in the four cell lines.   
After proving the effectiveness of the fraction on the movement of the cells in 
2D, the effect on 3D motility or invasiveness was determined. The invasion assay 
results showed a decrease in around 50% in treated cells invasiveness. Invasion is a 
very important step in metastasis as mentioned earlier. The tumour cells have to 
invade the surrounding tissue, ECM and vessels in order to reach farther metastatic 
sites (Lambrechts, Van Troy, & Am, 2004). 
Adhesion is a confusing process in cellular motility. An increased or 
decreased adhesion both lead to altered cellular motility. In fact, while cells need to 
lose their adhesions in order to move, adhesion is important for the cells to attach to 
ECM to polarize and move. On the other hand, increased adhesion hinders the cells 
rendering them immotile (Cox, Sastry, & Huttenlocher, 2001). Upon treatment with 
DC F2 fraction, cells showed increased adhesion. This phenotype was observed in 
the time-lapse experiments were the cells looked hindered and moved in their places. 
After observing these phenotypes, it was intriguing to look at these effects at 
the molecular levels. Investigating the levels of expression of Rho, Rac and CDC42 
in-vitro upon treatment was then assessed. Since Rho is needed for the formation of 
stress fibers and motility, the obtained decrease in RhoA activation after treatment is 
expected according to the time lapse and wound healing assays. In fact, as Rho is 
also involved in the turnover between focal complexes/adhesions, it is needed for the 
maturation of these complexes into adhesions which helps in detachment and 
movement (Karelsson, Pedersen, Wang, & Brakebusch, 2009).  On the other hand, 
levels of Rac activation were found to be increased in the treatment versus the 
control. This is consistent with the results obtained from the adhesion assay. In fact, 
an increase in Rac which helps in recruitment of focal complexes at the edges of 
lamellipodia is expected with the increased adhesion phenotype. Focal complexes are 
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responsible for docking the cells to the ECM, increased focal complexes to focal 
adhesion ratio leads to decreased cellular movement. The decrease in Rho and 
increase in Rac are expected observations since the time-lapse showed that the cells 
are stuck in their positions (Nobes & Hall, 1995; Rottner, Hall, & Small, 1999). In 
addition to that Rho and Rac are known to have antagonistic roles in cellular motility 
(El-Sibai, et al., 2008). CDC42 which is responsible for the filopodia formation also 
showed to have a decreased activity after treatment with the chosen fraction 
(Burbelo, Drechsel, & Hall, 1995).  
The immunostaining assays show a decrease in the stress fibers formation 
upon the treatment. This is logical since we have a decrease in active Rho levels 
which would lead to a decrease in the formation of actin filaments and thus a 
decreased motility phenotype.  
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Chapter 4 
Conclusion 
The current results showed a pronounced and promising effect of DC fraction 
on cancer motility and metastasis, more studies have to be carried out to look at the 
effect of extract on focal complexes and adhesion. Ongoing in vivo studies are also 
needed to further confirm the obtained results. Daucus carota has till now satisfied 
the guidelines set to examine the anti-cancer potential of plant derived drugs. Further 
purifications of the fraction are being performed to isolate the active compound 
responsible for the observed effect of DC on cancer cells.  The significance of this 
study is towards reaching a potential DC cancer therapy specifically targeting cancer 
motility and metastasis. 
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